Mountain Crest Acquisition Corp. II
Status: Closed Deal
U=S+R
R=S/10
| IPO Proceeds, $M | $57.50M |
|---|---|
| IPO Date | Jan 8, 2021 |
| CEO | Suying Liu |
| Left Lead | Chardan |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 9+6 |
| IPO Sector | General ▶ |
| IPO Geography | US/Canada |
| Target Company | Better Therapeutics |
| Deal Announced | Apr 7, 2021 |
| Deal Size, $M | $184.00M |
| Deal Sector | Healthcare |
| Deal Geography | US/Canada |
| SEC Filings |
www.sec.gov 
|
| Approval Vote | Oct 27, 2021 |
| Amendment Vote | TBD |
| Closing Date | Oct 28, 2021 |
Formerly MCAD
BTTX
| Price | $0.00 |
|---|---|
| Last closing price | $0.04 |
| H/L, today | $0.00 / $0.00 |
| H/L, 52-week | $0.14 / $1.61 |
| Volume, today | 5 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in to view structure, cap table, and calendar of events.